Capital World Investors Has $1.16 Billion Stock Holdings in Pfizer Inc. (NYSE:PFE)

Capital World Investors lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 18.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 43,615,408 shares of the biopharmaceutical company's stock after selling 10,072,797 shares during the period. Capital World Investors owned 0.77% of Pfizer worth $1,157,108,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. PSI Advisors LLC lifted its stake in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 385 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after acquiring an additional 391 shares in the last quarter. D Orazio & Associates Inc. increased its holdings in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 391 shares during the last quarter. Lipe & Dalton raised its stake in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 400 shares in the last quarter. Finally, Oliver Luxxe Assets LLC lifted its holdings in Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after purchasing an additional 401 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock traded down $0.07 during mid-day trading on Monday, hitting $22.07. 31,814,050 shares of the company were exchanged, compared to its average volume of 40,452,372. The business has a fifty day moving average of $24.81 and a 200 day moving average of $26.11. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a market capitalization of $125.17 billion, a PE ratio of 15.65, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PFE. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, UBS Group dropped their price target on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.07.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.